Author(s) Details:
Alexandru Calin Grigorescu
Compartment of Medical Oncology, Clinical Hospital for Nephrology “Dr Carol Davila”, Calea Grivitei Nr4, Bucharest, Romania
This section is a part of the chapter: Tirosine Kinase Inhibitors (TKI) Used in the Treatment of Non-Small Cell Lung Cancer (NSCLC) Based on Specific Genetic Alterations
Identification of genetic changes that can be driver mutations: EGFR, ALK, PI3K/AKT/mTOR, RAS-MAPK, RET, MET, BRAF, and NTRK/ROS1 guides appropriate treatment. The approval and adoption of therapeutic providers that target these genetic alterations has led to a 35% decrease in mortality among men with NSCLC diagnosed in 2001 to 26% in 2014. “Similar rates have been found among women with NSCLC. Despite these new therapeutic agents for patients with advanced NSCLC, the development of resistance and disease progression occurs in the majority of patients. Patients develop resistance to these agents. The emergence of resistance to therapeutic agents has led to research into drugs that can overcome these resistance mechanisms. Next-generation sequencing, which can be performed on tumor tissue obtained by biopsy or on circulating tumor DNA (ct DNA) in the blood, is now the standard of care for all patients with advanced NSCLC. This identifies actionable mutations and resistance mechanisms” (Majeed et al., 2021).
How to Cite
Nasrat, A. M., Nasrat, S. A., Nasrat, R. M., Nasrat, M. M., & Babiker, S. Y. (2025). Helicobacter pylori and Hyperuricemia: Revisiting Gout Diagnosis in Young Adults with Normal Renal Function. Medical Science: Trends and Innovations Vol. 4, 1–8. https://doi.org/10.9734/bpi/msti/v4/3641